OBJECTIVES Frequent legislative changes that have brought the Slovak health care reform over the past decade, reflected also on drug policy and especially on the prices of medicines and total consumption of medicines. Generic substitution was introduced to save both health insurance and patient’s finances. METHODS Data on prices and consumption of lipid-lowering agent medicines were collected from Slovak Ministry of Health and Health insurance.  Data processing, we used a uniform methodology recommended by the WHO - ATC / DDD classification and basic statistical methods of observing. In case of national data, we reported consumption in units of DDD per 1,000 inhabitants for one day (DID). RESULTS A class of lipid-lowering agent medicines (C10A) poses in recent years on Slovak market expanding group. Its number significantly increased in direct proportion with the introduction of generic drugs,  mainly after 2004, when generic substitution was enacted and later after 2011, when mandatory generic prescribing entry into the force. The proportion of total medicines and generic drugs in the group C10A were x_{total-medicines/%generic-drugs}=55/74,6 types and x_{total-medicines/%generic-drugs}=203/94 types. The number of generic drugs with atorvastatin ranged x=4-18, rosuvastatin x=3-11, simvastatin x=7-7, fluvastatin x=1-1, lovastatin x=1-5. The  consumption of medicines with atorvastatin x